【24h】

Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: A randomized controlled study

机译:普萘洛尔与泼尼松龙,普萘洛尔联合泼尼松龙在婴儿血管瘤治疗中的作用:一项随机对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

Aims and Objectives: The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas. Material and Methods: A prospective study of 30 patients aged 1 week-8 months was randomized into three equal groups. These were as follows: A, propranolol (2-3 mg/kg/d); B, prednisolone (1-4 mg/kg/d); and C, receiving both for a minimum duration of 3 months. Dimensions, color, consistency, ultrasonography, photographic documentation based on Visual Analogue Scale (VAS) were recorded before and periodically after starting treatment. A minimum 75% improvement was considered as success with no regrowth up to 1 month of stopping treatment. Results: Mean initial response time (days) in A (4.1 ± 3.3 SD) and C (4.7 ± 3.4SD) was significantly lower than B (9.78 ± 7.8SD) (p < 0.047). Significant change in consistency was noted very early in A (24 hours) compared to B and C (8 days). VAS results are as follows: (a) color fading - significant reduction in A within 48 hours compared to B and C (p = 0.025), (b) flattening - more significant and earlier in A and C than B (p < 0.05), and (c) mean reduction in size: significant in A and C at 3 months (p = 0.005, p = 0.005), 6 months (p = 0.005, p = 0.008), 12 months (p = 0.005, p = 0.008), and 18 months (p = 0.02, p = 0.04), whereas in B, it was seen only at 6 months (p = 0.008). Conclusions: Propranolol had a consistent, rapid therapeutic effect compared to prednisolone. A combination of the two had a comparable but not higher efficacy than propranolol alone. Prednisolone was associated with a higher number of complications, thereby decreasing patient compliance.
机译:目的和目的:本研究的目的是比较口服普萘洛尔与泼尼松龙的疗效以及两者在治疗可能毁容或功能威胁的婴儿血管瘤中的疗效。材料与方法:前瞻性研究将30位1周至8个月大的患者随机分为三组。它们如下:A,普萘洛尔(2-3 mg / kg / d); B,泼尼松龙(1-4 mg / kg / d);和C,均接受至少3个月的培训。在开始治疗之前和之后定期记录尺寸,颜色,稠度,超声检查,基于视觉模拟量表(VAS)的照相文件。至少75%的改善被认为是成功的,直到停止治疗1个月都没有再生长。结果:A(4.1±3.3 SD)和C(4.7±3.4SD)的平均初始响应时间(天)显着低于B(9.78±7.8SD)(p <0.047)。与B和C(8天)相比,在A(24小时)很早就注意到一致性的显着变化。 VAS结果如下:(a)褪色-与B和C相比,A在48小时内显着减少(p = 0.025),(b)变平-与B相比,A和C中更显着且更早(p <0.05)和(c)尺寸的平均减少:A和C在3个月(p = 0.005,p = 0.005),6个月(p = 0.005,p = 0.008),12个月(p = 0.005,p = 0.008)时显着)和18个月(p = 0.02,p = 0.04),而在B中,仅在6个月时可见(p = 0.008)。结论:与泼尼松龙相比,普萘洛尔具有一致,快速的治疗效果。两者的组合比单独使用普萘洛尔具有可比但不更高的功效。泼尼松龙与更高数量的并发症相关,从而降低了患者的依从性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号